The likelihood of severe complications after emergency colon cancer surgery is significantly higher over the weekend, according to a study in the latest issue of JNCCN – Journal of the National Comprehensive Cancer Network.
Women who consumed a low-fat diet had a significantly reduced risk of death after breast cancer. However, women with other cancers who were also on a low-fat diet did not experience the same effect, according to new results from the Women's Health Initiative Dietary Modification trial that were presented at the 2018 American Society of Clinical Oncology Annual Meeting.
Contrary to current perceptions, certain African-American men with advanced prostate cancer have as good a chance of survival as white men and might actually have a small advantage, according to a new analysis of more than 8,000 patients who participated in clinical trials.
African-American men with advanced prostate cancer might be more responsive than white men to an anti-androgen drug and steroids, according to a study led by Duke Cancer Institute researchers.
Loxo Oncology Inc. announced interim clinical data from the LOXO-292 global phase I LOXO-292 Investigated to Block RET-altered Tumors dose escalation trial.
Genentech, announced positive results from the phase III IMpower150 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel for the initial treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer.
In follow-up data from the phase III ALEX study, an initial treatment Alecensa (alectinib) significantly reduced the risk of disease progression or death by 57 percent (hazard ratio= 0.43, 95 percent CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, as assessed by the investigator.
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at MD Anderson Cancer Center reports in the New England Journal of Medicine.
Novartis announced positive results from the third phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer.
In a randomized, phase II trial led by researchers at MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates in patients with small cell lung cancer.
